Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Larimar Therapeutics, Inc. (LRMR) had Non-Operating Income/Expense of $1.52M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-62.50M |
|
-- |
|
-- |
|
$64.02M |
|
$-64.02M |
|
|
Non-Operating Income/Expense |
$1.52M |
$-62.50M |
|
$-62.50M |
|
$-62.50M |
|
$-62.50M |
|
$-62.50M |
|
$-62.50M |
|
$-64.02M |
|
$-64.09M |
|
72.95M |
|
72.95M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$142.02M |
|
$0.62M |
|
$3.82M |
|
$145.84M |
|
$64.80M |
|
-- |
|
$2.96M |
|
$67.76M |
|
$78.08M |
|
$78.08M |
|
$78.08M |
|
83.09M |
|
| Cash Flow Statement Financials | |
$-113.20M |
|
$100.31M |
|
$65.09M |
|
$33.82M |
|
$86.02M |
|
$52.19M |
|
$7.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-113.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-80.04% |
|
-80.04% |
|
-42.85% |
|
-80.04% |
|
$0.94 |
|
$-1.55 |
|
$-1.55 |
|